Turner syndrome is a rare condition in women that is associated with either complete or partial loss of one X chromosome, often in mosaic karyotypes. Turner syndrome is associated with short stature, delayed puberty, ovarian dysgenesis, hypergonadotropic hypogonadism, infertility, congenital malformations of the heart, endocrine disorders such as type 1 and type 2 diabetes mellitus, osteoporosis and autoimmune disorders. Morbidity and mortality are increased in women with Turner syndrome compared with the general population and the involvement of multiple organs through all stages of life necessitates a multidisciplinary approach to care. Despite an often conspicuous phenotype, the diagnostic delay can be substantial and the average age at diagnosis is around 15 years of age. However, numerous important clinical advances have been achieved, covering all specialty fields involved in the care of girls and women with Turner syndrome. Here, we present an updated Review of Turner syndrome, covering advances in genetic and genomic mechanisms of disease, associated disorders and multidisciplinary approaches to patient management, including growth hormone therapy and hormone replacement therapy.
Turner syndrome is a rare disorder caused by a completely or partially missing X chromosome; diagnosis of this condition is often delayed.
Growth is usually compromised and short stature can be treated with growth hormone and oxandrolone, usually leading to substantial increases in final height.
Congenital heart abnormalities are frequent and every woman with Turner syndrome should be seen by a cardiologist at least once.
Most women with Turner syndrome experience primary or secondary hypergonadotropic hypogonadism, which necessitates treatment with hormone replacement therapy.
Compared with the general population, morbidity and mortality are increased in women with Turner syndrome owing to a broad swathe of diseases, demanding vigilance as the individual ages.
Optimal care for Turner syndrome necessitates a multidisciplinary team optimally situated within the framework of one hospital.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gravholt, C. H. et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur. J. Endocrinol. 177, G1–G70 (2017).
Lonberg, N. C. & Nielsen, J. Seresevskij-Turner’s syndrome or Turner’s syndrome [letter]. Hum. Genet. 38, 363–364 (1977).
El-Mansoury, M. et al. Chromosomal mosaicism mitigates stigmata and cardiovascular risk factors in Turner syndrome. Clin. Endocrinol. 66, 744–751 (2007).
Cameron-Pimblett, A., La, R. C., King, T. F. J., Davies, M. C. & Conway, G. S. The Turner Syndrome Life Course Project: karyotype-phenotype analyses across the lifespan. Clin. Endocrinol. 87, 532–538 (2017).
Rao, E. et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat. Genet. 16, 54–63 (1997).
Fukami, M., Seki, A. & Ogata, T. SHOX haploinsufficiency as a cause of syndromic and nonsyndromic short stature. Mol. Syndromol. 7, 3–11 (2016).
Marchini, A., Ogata, T. & Rappold, G. A. A. Track record on SHOX: from basic research to complex models and therapy. Endocr. Rev. 37, 417–448 (2016).
Corbitt, H. et al. TIMP3 and TIMP1 are risk genes for bicuspid aortic valve and aortopathy in Turner syndrome. PLOS Genet. 14, e1007692 (2018).
Trolle, C. et al. Widespread DNA hypomethylation and differential gene expression in Turner syndrome. Sci. Rep. 6, 34220 (2016).
Rabkin, S. W. The role matrix metalloproteinases in the production of aortic aneurysm. Prog. Mol. Biol. Transl Sci. 147, 239–265 (2017).
Sharma, A. et al. DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations. Clin. Epigenet. 7, 76 (2015).
Rajpathak, S. N. et al. Human 45,X fibroblast transcriptome reveals distinct differentially expressed genes including long noncoding RNAs potentially associated with the pathophysiology of Turner syndrome. PLOS ONE 9, e100076 (2014).
Zhang, R. et al. Gene expression analysis of induced pluripotent stem cells from aneuploid chromosomal syndromes. BMC Genomics 14 (Suppl. 5), 8 (2013).
Watanabe, M., Zinn, A. R., Page, D. C. & Nishimoto, T. Functional equivalence of human X- and Y-encoded isoforms of ribosomal protein S4 consistent with a role in Turner syndrome. Nat. Genet. 4, 268–271 (1993).
Naqvi, S., Bellott, D. W., Lin, K. S. & Page, D. C. Conserved microRNA targeting reveals preexisting gene dosage sensitivities that shaped amniote sex chromosome evolution. Genome Res. 28, 474–483 (2018).
Bellott, D. W. et al. Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. Nature 508, 494–499 (2014).
Pessia, E., Makino, T., Bailly-Bechet, M., McLysaght, A. & Marais, G. A. Mammalian X chromosome inactivation evolved as a dosage-compensation mechanism for dosage-sensitive genes on the X chromosome. Proc. Natl Acad. Sci. USA 109, 5346–5351 (2012).
Yan, F., Wang, X. & Zeng, Y. 3D genomic regulation of lncRNA and Xist in X chromosome. Semin. Cell Dev. Biol. 90, 174–180 (2018).
Miyake, N. et al. KDM6A point mutations cause Kabuki syndrome. Hum. Mutat. 34, 108–110 (2013).
Skakkebaek, A. et al. DNA hypermethylation and differential gene expression associated with Klinefelter syndrome. Sci. Rep. 8, 13740 (2018).
Raznahan, A. et al. Sex-chromosome dosage effects on gene expression in humans. Proc. Natl Acad. Sci. USA 115, 7398–7403 (2018).
Prakash, S. K. et al. Autosomal and X chromosome structural variants are associated with congenital heart defects in Turner syndrome: the NHLBI GenTAC registry. Am. J. Med. Genet. A 170, 3157–3164 (2016).
Lleo, A., Moroni, L., Caliari, L. & Invernizzi, P. Autoimmunity and Turner’s syndrome. Autoimmun. Rev. 11, A538–A543 (2012).
Berglund, A. et al. 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I. Clin. Exp. Immunol. 195, 364–368 (2018).
Urbach, A. & Benvenisty, N. Studying early lethality of 45,XO (Turner’s syndrome) embryos using human embryonic stem cells. PLOS ONE 4, e4175 (2009).
Hassold, T. J. Chromosome abnormalities in human reproductive wastage. Trends. Genet. 2, 105–110 (1986).
Stochholm, K., Juul, S., Juel, K., Naeraa, R. W. & Gravholt, C. H. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J. Clin. Endocrinol. Metab. 91, 3897–3902 (2006).
Berglund, A. et al. Changes in the cohort composition of Turner syndrome and severe non-diagnosis of Klinefelter, 47,XXX and 47,XYY syndrome: a nationwide cohort study. Orphanet J. Rare Dis. 14, 16 (2019).
Tuke, M. A. et al. Mosaic Turner syndrome shows reduced penetrance in an adult population study. Genet. Med. 21, 877–886 (2018).
Viuff, M. H. et al. Only a minority of sex chromosome abnormalities are detected by the Danish national prenatal screening program for Down syndrome. Hum. Reprod. 30, 2419–2426 (2015).
Bianchi, D. W. Turner syndrome: new insights from prenatal genomics and transcriptomics. Am. J. Med. Genet. C 181, 29–33 (2019).
Jeon, K. C., Chen, L. S. & Goodson, P. Decision to abort after a prenatal diagnosis of sex chromosome abnormality: a systematic review of the literature. Genet. Med. 14, 27–38 (2012).
Gravholt, C. H., Juul, S., Naeraa, R. W. & Hansen, J. Morbidity in Turner syndrome. J. Clin. Epidemiol. 51, 147–158 (1998).
Mortensen, K. H., Andersen, N. H. & Gravholt, C. H. Cardiovascular phenotype in Turner syndrome —integrating cardiology, genetics, and endocrinology. Endocr. Rev. 33, 677–714 (2012).
Schoemaker, M. J., Swerdlow, A. J., Higgins, C. D., Wright, A. F. & Jacobs, P. A. Mortality in women with Turner syndrome in Great Britain: a national cohort study. J. Clin. Endocrinol. Metab. 93, 4735–4742 (2008).
Stochholm, K. et al. Socio-economic parameters and mortality in Turner syndrome. Eur. J. Endocrinol. 166, 1013–1019 (2012).
Schoemaker, M. J., Swerdlow, A. J., Higgins, C. D., Wright, A. F. & Jacobs, P. A. Cancer incidence in women with Turner syndrome in Britain: a national cohort study. Lancet Oncol. 9, 239–246 (2008).
Ji, J., Zoller, B., Sundquist, J. & Sundquist, K. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: a national cohort study. Int. J. Cancer. 139, 754–758 (2016).
Bosze, P., Toth, A. & Torok, M. Hormone replacement and the risk of breast cancer in Turner’s syndrome. N. Engl. J. Med. 355, 2599–2600 (2006).
Swerdlow, A. J. et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study. J. Clin. Endocrinol. Metab. 102, 1661–1672 (2017).
Calanchini, M. et al. Liver biochemical abnormalities in Turner syndrome: a comprehensive characterization of an adult population. Clin. Endocrinol. 89, 667–676 (2018).
Hamza, R. T. et al. Renal anomalies in patients with Turner syndrome: is scintigraphy superior to ultrasound? Am. J. Med. Genet. A 170, 355–362 (2016).
Bois, E. et al. Otologic disorders in Turner syndrome. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 135, 21–24 (2018).
Cools, M., Looijenga, L. H., Wolffenbuttel, K. P. & T’Sjoen, G. Managing the risk of germ cell tumourigenesis in disorders of sex development patients. Endocr. Dev. 27, 185–196 (2014).
Rojek, A., Obara-Moszynska, M., Kolesinska, Z., Rabska-Pietrzak, B. & Niedziela, M. Molecular detection and incidence of Y chromosomal material in patients with Turner syndrome. Sex. Dev. 11, 254–261 (2017).
Singh, R. P. & Carr, D. H. The anatomy and histology of XO human embryos and fetuses. Anat. Rec. 155, 369–383 (1966).
Tanaka, T. et al. Frequencies of spontaneous breast development and spontaneous menarche in Turner syndrome in Japan. Clin. Pediatr. Endocrinol. 24, 167–173 (2015).
Carpini, S. et al. Spontaneous puberty in girls with early diagnosis of Turner syndrome. Arq. Bras. Endocrinol. Metabol. 56, 653–657 (2012).
Pasquino, A. M., Passeri, F., Pucarelli, I., Segni, M. & Municchi, G. Spontaneous pubertal development in Turner’s syndrome. Italian Study Group for Turner’s Syndrome. J. Clin. Endocrinol. Metab. 82, 1810–1813 (1997).
Borgstrom, B. et al. Fertility preservation in girls with Turner syndrome: prognostic signs of the presence of ovarian follicles. J. Clin. Endocrinol. Metab. 94, 74–80 (2009).
Birkebaek, N., Cruger, D., Hansen, J., Nielsen, J. & Bruun-Petersen, G. Fertility and pregnancy outcome in Danish women with Turner syndrome. Clin. Genet. 61, 35–39 (2002).
Bernard, V. et al. Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. Hum. Reprod. 31, 782–788 (2016).
Bryman, I. et al. Pregnancy rate and outcome in Swedish women with Turner syndrome. Fertil. Steril. 95, 2507–2510 (2011).
Mortensen, K. H., Rohde, M. D., Uldbjerg, N. & Gravholt, C. H. Repeated spontaneous pregnancies in 45,X Turner syndrome. Obstet. Gynecol. 115, 446–449 (2010).
Foudila, T., Söderström-Anttila, V. & Hovatta, O. Turner’s syndrome and pregnancies after oocyte donation. Hum. Reprod. 14, 532–535 (1999).
Practice Committee of the American Society for Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil. Steril. 83, 1074–1075 (2005).
Chevalier, N. et al. Materno-fetal cardiovascular complications in Turner syndrome after oocyte donation: insufficient prepregnancy screening and pregnancy follow-up are associated with poor outcome. J. Clin. Endocrinol. Metab. 96, E260–E267 (2011).
Hagman, A. et al. Morbidity and mortality after childbirth in women with Turner karyotype. Hum. Reprod. 28, 1961–1973 (2013).
Cadoret, F. et al. Pregnancy outcome in Turner syndrome: a French multi-center study after the 2009 guidelines. Eur. J. Obstet. Gynecol. Reprod. Biol. 229, 20–25 (2018).
Ros, C., Alobid, I., Balasch, J., Mullol, J. & Castelo-Branco, C. Turner’s syndrome and other forms of congenital hypogonadism impair quality of life and sexual function. Am. J. Obstet. Gynecol. 208, 484–486 (2013).
Sheaffer, A. T., Lange, E. & Bondy, C. A. Sexual function in women with Turner syndrome. J. Womens Health 17, 27–33 (2008).
Gravholt, C. H. et al. Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur. J. Endocrinol. 155, 583–592 (2006).
Gravholt, C. H. & Naeraa, R. W. Reference values for body proportions and body composition in adult women with Turner’s syndrome. Am. J. Med. Genet. 72, 403–408 (1997).
Wooten, N., Bakalov, V. K., Hill, S. & Bondy, C. A. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J. Clin. Endocrinol. Metab. 93, 2109–2114 (2008).
Gravholt, C. H. et al. Short term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity. A randomized double-blind, placebo-controlled cross-over study. Pediatrics 110, 889–896 (2002).
Gravholt, C. H. et al. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome. The impact of sex hormone replacement. Diabetes Care 21, 1062–1070 (1998).
Taboada, M. et al. Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndrome. J. Clin. Endocrinol. Metab. 96, 3502–3510 (2011).
Calcaterra, V. et al. Metabolic syndrome in Turner syndrome and relation between body composition and clinical, genetic, and ultrasonographic characteristics. Metab. Syndr. Relat. Disord. 12, 159–164 (2014).
Landin-Wilhelmsen, K., Bryman, I. & Wilhelmsen, L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J. Clin. Endocrinol. Metab. 86, 4166–4170 (2001).
Gravholt, C. H., Klausen, I. C., Weeke, J. & Christiansen, J. S. Lp(a) and lipids in adult Turner’s syndrome: impact of treatment with 17β-estradiol and norethisterone. Atherosclerosis 150, 201–208 (2000).
Ross, J. L. et al. Lipid abnormalities in Turner syndrome. J. Pediatr. 126, 242–245 (1995).
Van, P. L., Bakalov, V. K. & Bondy, C. A. Monosomy for the X-chromosome is associated with an atherogenic lipid profile. J. Clin. Endocrinol. Metab. 91, 2867–2870 (2006).
Brun, S. et al. Five-year randomized study demonstrates blood pressure increases in young women with Turner syndrome regardless of estradiol dose. Hypertension 73, 242–248 (2019).
Freriks, K. et al. Standardized multidisciplinary evaluation yields significant previously undiagnosed morbidity in adult women with Turner syndrome. J. Clin. Endocrinol. Metab. 96, E1517–E1526 (2011).
Hjerrild, B. E. et al. Delayed β-cell response and glucose intolerance in young women with Turner syndrome. BMC Endocr. Disord. 11, 6 (2011).
Bakalov, V. K. et al. Impaired insulin secretion in the Turner metabolic syndrome. J. Clin. Endocrinol. Metab. 89, 3516–3520 (2004).
Sun, L. et al. Glucose metabolism in Turner syndrome. Front. Endocrinol. 10, 49 (2019).
Bakalov, V. K., Cheng, C., Zhou, J. & Bondy, C. A. X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J. Clin. Endocrinol. Metab. 94, 3289–3296 (2009).
Bakalov, V. K. & Bondy, C. A. Fracture risk and bone mineral density in Turner syndrome. Rev. Endocr. Metab. Disord. 9, 145–151 (2008).
Gravholt, C. H. et al. Increased fracture rates in Turner’s syndrome: a nationwide questionnaire survey. Clin. Endocrinol. 59, 89–96 (2003).
Landin-Wilhelmsen, K., Bryman, I., Windh, M. & Wilhelmsen, L. Osteoporosis and fractures in Turner syndrome–importance of growth promoting and oestrogen therapy. Clin. Endocrinol. 51, 497–502 (1999).
Bakalov, V. K. et al. Bone mineral density and fractures in Turner syndrome. Am. J. Med. 115, 259–264 (2003).
Ross, J. L., Long, L. M., Feuillan, P., Cassorla, F. & Cutler, G. B. J. Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner’s syndrome. J. Clin. Endocrinol. Metab. 73, 355–359 (1991).
Shi, K. et al. Body composition and bone mineral status in patients with Turner syndrome. Sci. Rep. 6, 38026 (2016).
Holroyd, C. R. et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos. Int. 21, 2093–2099 (2010).
Hansen, S., Brixen, K. & Gravholt, C. H. Compromised trabecular microarchitecture and lower finite element estimates of radius and tibia bone strength in adults with Turner syndrome: a cross-sectional study using high-resolution-pQCT. J. Bone Miner. Res. 27, 1794–1803 (2012).
Carrascosa, A. et al. Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients. J. Bone Miner. Res. 15, 2005–2010 (2000).
Cleemann, L. et al. Long-term hormone replacement therapy preserves bone mineral density in Turner syndrome. Eur. J. Endocrinol. 161, 251–257 (2009).
Nguyen, H. H. et al. Delay in estrogen commencement is associated with lower bone mineral density in Turner syndrome. Climacteric 20, 436–441 (2017).
Hanton, L., Axelrod, L., Bakalov, V. & Bondy, C. A. The importance of estrogen replacement in young women with Turner syndrome. J. Womens Health 12, 971–977 (2003).
Jorgensen, K. T. et al. Autoimmune diseases in women with Turner’s syndrome. Arthritis Rheum. 62, 658–666 (2010).
Marild, K., Stordal, K., Hagman, A. & Ludvigsson, J. F. Turner syndrome and celiac disease: a case-control study. Pediatrics 137, e20152232 (2016).
Mortensen, K. H. et al. Increased prevalence of autoimmunity in Turner syndrome—influence of age. Clin. Exp. Immunol. 156, 205–210 (2009).
Mohamed, S. O. O. et al. Prevalence of autoimmune thyroid diseases among the Turner Syndrome patients: meta-analysis of cross sectional studies. BMC Res. Notes 11, 842 (2018).
El Mansoury, M. et al. Hypothyroidism is common in Turner syndrome: results of a five-year follow-up. J. Clin. Endocrinol. Metab. 90, 2131–2135 (2005).
Bakalov, V. K. et al. Autoimmune disorders in women with Turner syndrome and women with karyotypically normal primary ovarian insufficiency. J. Autoimmun. 38, 315–321 (2012).
Elsheikh, M., Wass, J. A. & Conway, G. S. Autoimmune thyroid syndrome in women with Turner’s syndrome — the association with karyotype. Clin. Endocrinol. 55, 223–226 (2001).
Libert, C., Dejager, L. & Pinheiro, I. The X chromosome in immune functions: when a chromosome makes the difference. Nat. Rev. Immunol. 10, 594–604 (2010).
Larizza, D., Calcaterra, V. & Martinetti, M. Autoimmune stigmata in Turner syndrome: when lacks an X chromosome. J. Autoimmun. 33, 25–30 (2009).
Gawlik, A. M. et al. Immunological profile and predisposition to autoimmunity in girls with Turner syndrome. Front. Endocrinol. 9, 307 (2018).
Invernizzi, P. et al. X chromosome monosomy: a common mechanism for autoimmune diseases. J. Immunol. 175, 575–578 (2005).
El-Mansoury, M. et al. Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. Clin. Endocrinol. 68, 485–490 (2008).
Gravholt, C. H., Naeraa, R. W., Fisker, S. & Christiansen, J. S. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth axis aberrations in adult Turner’s syndrome, with important modulations by treatment with 17β-estradiol. J. Clin. Endocrinol. Metab. 82, 2570–2577 (1997).
Roulot, D. et al. Vascular involvement of the liver in Turner’s syndrome. Hepatology 39, 239–247 (2004).
Elsheikh, M., Hodgson, H. J., Wass, J. A. & Conway, G. S. Hormone replacement therapy may improve hepatic function in women with Turner’s syndrome. Clin. Endocrinol. 55, 227–231 (2001).
Gravholt, C. H., Poulsen, H. E., Ott, P., Christiansen, J. S. & Vilstrup, H. Quantitative liver functions in Turner syndrome with and without hormone replacement therapy. Eur. J. Endocrinol. 156, 679–686 (2007).
De Groote, K. et al. Increased aortic stiffness in prepubertal girls with Turner syndrome. J. Cardiol. 69, 201–207 (2017).
Klaskova, E. et al. Increased prevalence of bicuspid aortic valve in Turner syndrome links with karyotype: the crucial importance of detailed cardiovascular screening. J. Pediatr. Endocrinol. Metab. 30, 319–325 (2017).
Mortensen, K. H., Gopalan, D., Norgaard, B. L., Andersen, N. H. & Gravholt, C. H. Multimodality cardiac imaging in Turner syndrome. Cardiol. Young 26, 831–841 (2016).
Viuff, M. H. et al. Coronary artery anomalies in Turner syndrome. J. Cardiovasc. Comput. Tomogr. 10, 480–484 (2016).
Mortensen, K. H. et al. Cardiovascular imaging in Turner syndrome: state-of-the-art practice across the lifespan. Heart 104, 1823–1831 (2018).
Ho, V. B. et al. Major vascular anomalies in Turner syndrome: prevalence and magnetic resonance angiographic features. Circulation 110, 1694–1700 (2004).
Yetman, A. T. et al. Clinical and echocardiographic prevalence and detection of congenital and acquired cardiac abnormalities in girls and women with the Turner syndrome. Am. J. Cardiol. 122, 327–330 (2018).
Haak, M. C., Bartelings, M. M., Gittenberger-De Groot, A. C. & van Vugt, J. M. Cardiac malformations in first-trimester fetuses with increased nuchal translucency: ultrasound diagnosis and postmortem morphology. Ultrasound Obstet. Gynecol. 20, 14–21 (2002).
Lara, D. A., Ethen, M. K., Canfield, M. A., Nembhard, W. N. & Morris, S. A. A population-based analysis of mortality in patients with Turner syndrome and hypoplastic left heart syndrome using the Texas Birth Defects Registry. Congenit. Heart Dis. 12, 105–112 (2017).
Chew, J. D. et al. Heart transplantation in children with Turner syndrome: analysis of a linked dataset. Pediatr. Cardiol. 39, 610–616 (2018).
Matura, L. A., Ho, V. B., Rosing, D. R. & Bondy, C. A. Aortic dilatation and dissection in Turner syndrome. Circulation 116, 1663–1670 (2007).
Mortensen, K. H. et al. Aortic growth rates are not increased in Turner syndrome — a prospective CMR study. Eur. Heart J. Cardiovasc. Imaging https://doi.org/10.1093/ehjci/jez065 (2019).
Mortensen, K. H., Erlandsen, M., Andersen, N. H. & Gravholt, C. H. Prediction of aortic dilation in Turner syndrome — enhancing the use of serial cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 15, 47 (2013).
Subramaniam, D. R. et al. Continuous measurement of aortic dimensions in Turner syndrome: a cardiovascular magnetic resonance study. J. Cardiovasc. Magn. Reson. 19, 20 (2017).
Mortensen, K. H. et al. Carotid intima-media thickness is increased in Turner syndrome: multifactorial pathogenesis depending on age, blood pressure, cholesterol and oestrogen treatment. Clin. Endocrinol. 77, 844–851 (2012).
Schoepp, M. et al. Coronary calcification in adults with Turner syndrome. Genet. Med. 20, 664–668 (2017).
Schouten, J. N., Verheij, J. & Seijo, S. Idiopathic non-cirrhotic portal hypertension: a review. Orphanet J. Rare Dis. 10, 67 (2015).
Gravholt, C. H. et al. Coagulation and fibrinolytic disturbances are related to carotid intima thickness and arterial blood pressure in Turner syndrome. Clin. Endocrinol. 76, 649–656 (2012).
Gravholt, C. H. et al. Clinical and epidemiological description of aortic dissection in Turner’s syndrome. Cardiol. Young 16, 430–436 (2006).
Carlson, M., Airhart, N., Lopez, L. & Silberbach, M. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the International Turner Syndrome Aortic Dissection Registry. Circulation 126, 2220–2226 (2012).
Carlson, M. & Silberbach, M. Dissection of the aorta in Turner syndrome: two cases and review of 85 cases in the literature. J. Med. Genet. 44, 745–749 (2007).
De Groote, K. et al. Abnormal aortic arch morphology in Turner syndrome patients is a risk factor for hypertension. Heart Vessels 30, 618–625 (2014).
Turtle, E. J., Sule, A. A., Webb, D. J. & Bath, L. E. Aortic dissection in children and adolescents with Turner syndrome: risk factors and management recommendations. Arch. Dis. Child. 100, 662–666 (2015).
Nathwani, N. C., Unwin, R., Brook, C. G. & Hindmarsh, P. C. Blood pressure and Turner syndrome. Clin. Endocrinol. 52, 363–370 (2000).
Lopez, L. et al. Turner syndrome is an independent risk factor for aortic dilation in the young. Pediatrics 121, e1622–e1627 (2008).
Elsheikh, M., Casadei, B., Conway, G. S. & Wass, J. A. Hypertension is a major risk factor for aortic root dilatation in women with Turner’s syndrome. Clin. Endocrinol. 54, 69–73 (2001).
Hjerrild, B. E. et al. Thoracic aortopathy in Turner syndrome and the influence of bicuspid aortic valves and blood pressure: a CMR study. J. Cardiovasc. Magn. Res. 12, 12 (2010).
Langrish, J. P. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 53, 805–811 (2009).
De Groote, K. et al. Arterial hypertension in Turner syndrome: a review of the literature and a practical approach for diagnosis and treatment. J. Hypertens. 33, 1342–1351 (2015).
Zuckerman-Levin, N. et al. Physiological and catecholamine response to sympathetic stimulation in Turner syndrome. Clin. Endocrinol. 64, 410–415 (2006).
Gravholt, C. H., Hansen, K. W., Erlandsen, M., Ebbehoj, E. & Christiansen, J. S. Nocturnal hypertension and impaired sympathovagal tone in Turner syndrome. J. Hypertens. 24, 353–360 (2006).
Pedersen, T. A. et al. High long-term morbidity in repaired aortic coarctation: weak association with residual arch obstruction. Congenit. Heart Dis. 6, 573–582 (2011).
Baguet, J. P. et al. Structural and functional abnormalities of large arteries in the Turner syndrome. Heart 91, 1442–1446 (2005).
Sozen, A. B. et al. Left ventricular thickness is increased in nonhypertensive Turner’s syndrome. Echocardiography 26, 943–949 (2009).
Trolle, C. et al. Low myocardial glucose uptake in Turner syndrome is unaffected by growth hormone: a randomized, placebo-controlled FDG-PET study. Clin. Endocrinol. 83, 133–140 (2015).
Andersen, N. H. et al. Subclinical left ventricle dysfunction in normotensive women with Turner’s syndrome. Heart 92, 1516–1517 (2006).
Devos, D. G. et al. Proximal aortic stiffening in Turner patients may be present before dilation can be detected: a segmental functional MRI study. J. Cardiovasc. Magn. Reson. 19, 27 (2017).
Ostberg, J. E. et al. Excess visceral and hepatic adipose tissue in Turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. J. Clin. Endocrinol. Metab. 90, 2631–2635 (2005).
Hong, D. S. & Reiss, A. L. Cognitive and neurological aspects of sex chromosome aneuploidies. Lancet Neurol. 13, 306–318 (2014).
Jez, W. et al. Social and medical determinants of quality of life and life satisfaction in women with Turner syndrome. Adv. Clin. Exp. Med. 27, 229–236 (2018).
Thyen, U. et al. Quality of health care in adolescents and adults with disorders/differences of sex development (DSD) in six European countries (dsd-LIFE). BMC Health Serv. Res. 18, 527 (2018).
Wolstencroft, J. & Skuse, D. Social skills and relationships in Turner syndrome. Curr. Opin. Psychiatry 32, 85–91 (2018).
Reis, C. T., de Assumpcao, M. S., Guerra-Junior, G. & de Lemos-Marini, S. H. V. Systematic review of quality of life in Turner syndrome. Qual. Life Res. 27, 1985–2006 (2018).
Van Pareren, Y. K. et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J. Clin. Endocrinol. Metab. 88, 1119–1125 (2003).
Li, P., Cheng, F. & Xiu, L. Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis. Endocr. Connect. 7, 573–583 (2018).
Quigley, C. A. et al. Mortality in children receiving growth hormone treatment of growth disorders: data from the Genetics and Neuroendocrinology of Short Stature International Study. J. Clin. Endocrinol. Metab. 102, 3195–3205 (2017).
Klein, K. O. et al. Estrogen replacement in Turner syndrome: literature review and practical considerations. J. Clin. Endocrinol. Metab. 103, 1790–1803 (2018).
Mauras, N. et al. Impact of route of administration on genotoxic oestrogens concentrations using oral versus transdermal oestradiol in girls with Turner syndrome. Clin. Endocrinol. 90, 155–161 (2019).
Cleemann, L. et al. Uterus and ovaries in girls and young women with Turner syndrome evaluated by ultrasound and magnetic resonance imaging. Clin. Endocrinol. 74, 756–761 (2011).
Gawlik, A. M. et al. Late-onset puberty induction by transdermal estrogen in Turner syndrome girls — a longitudinal study. Front. Endocrinol. 9, 23 (2018).
Koulouri, O., Ostberg, J. & Conway, G. S. Liver dysfunction in Turner’s syndrome: prevalence, natural history and effect of exogenous oestrogen. Clin. Endocrinol. 69, 306–310 (2008).
Cleemann, L. et al. Dosage of estradiol, bone and body composition in Turner syndrome: a 5-year randomized controlled clinical trial. Eur. J. Endocrinol. 176, 233–242 (2017).
van der Schouw, Y. T., van der, G. Y., Steyerberg, E. W., Eijkemans, J. C. & Banga, J. D. Age at menopause as a risk factor for cardiovascular mortality. Lancet 347, 714–718 (1996).
Rocca, W. A., Grossardt, B. R., Miller, V. M., Shuster, L. T. & Brown, R. D. Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause 19, 272–277 (2012).
Cintron, D. et al. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome: a systematic review and meta-analysis. Endocrine 55, 366–375 (2016).
Zuckerman-Levin, N. et al. Androgen replacement therapy in Turner syndrome: a pilot study. J. Clin. Endocrinol. Metab. 94, 4820–4827 (2009).
Devernay, M., Ecosse, E., Coste, J. & Carel, J. C. Determinants of medical care for young women with Turner syndrome. J. Clin. Endocrinol. Metab. 94, 3408–3413 (2009).
Gawlik, A. & Malecka-Tendera, E. Transitions in endocrinology: treatment of Turner’s syndrome during transition. Eur. J. Endocrinol. 170, R57–R74 (2013).
Nabhan, Z. M. & Eugster, E. A. Medical care of girls with Turner syndrome: where are we lacking? Endocr. Pract. 17, 747–752 (2011).
Ertl, D. A. et al. Health status, quality of life and medical care in adult women with Turner syndrome. Endocr. Connect. 7, 534–543 (2018).
The authors acknowledge the support of the Novo Nordisk Foundation, Hede Nielsens Fond, the Lundbeck foundation, the Augustinus Foundation, the Aase and Einar Danielsen Foundation and Aarhus University.
Nature Reviews Endocrinology thanks S. Christin-Maitre and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
An unbalanced structural abnormality in which the arms of the chromosome are mirror images of each other, consisting of two copies of either the long (q) arm or the short (p) arm. This leads to partial trisomy of the genes present in an isochromosome and partial monosomy of the genes in the lost arm.
- Ring chromosomes
Abnormal chromosomes whose ends have fused together to form a ring. Usually, a ring X chromosome contains much less genetic information than a normal X chromosome.
In women with 46,XX karyotype, the majority of genes on the second X chromosome are usually inactivated to prevent overdosage of gene products, in comparison with men, who only have one X chromosome. Inactivation of an X chromosome is a random process and takes place in every cell.
Normally, two copies of all genes are present because two chromosomes harbour one copy of each gene. However, if a gene is mutated, haploinsufficiency can arise because only the wild-type gene on the other chromosome is expressed, resulting in a lower level of the gene product and, possibly, disease.
- Triple test
A test originally used to detect the presence of a fetus with Down syndrome during pregnancy based on ultrasound measurement of the nuchal fold thickness of the fetus along with assessment of pregnancy-associated plasma protein A and free β-chorionic gonadotropin levels in the maternal circulation.
About this article
Cite this article
Gravholt, C.H., Viuff, M.H., Brun, S. et al. Turner syndrome: mechanisms and management. Nat Rev Endocrinol 15, 601–614 (2019). https://doi.org/10.1038/s41574-019-0224-4
Baylor University Medical Center Proceedings (2021)
Increased Insulin Concentrations During Growth Hormone Treatment in Girls With Turner Syndrome Are Ameliorated by Hormone Replacement Therapy
Frontiers in Endocrinology (2020)
Nursing Children and Young People (2020)
Current Opinion in Endocrine and Metabolic Research (2020)
Annales d'Endocrinologie (2020)